Get access to the exclusive HR Resources you need to succeed in 2018!
SHRM board member David Windley discusses how unconscious bias can derail workplace diversity efforts.
Is your employee handbook keeping up with the changing world of work? With SHRM's Employee Handbook Builder get peace of mind that your handbook is up-to-date.
Build competencies, establish credibility and advance your career—while earning PDCs—at SHRM Seminars in 12 cities across the U.S. this spring.
#SHRM18 will expand your perspective – on your organization, on your career, and on the way you approach HR. Join us in Chicago June 17-20, 2018
Policies will promote market competition to rein in rising prices
Members may download one copy of our sample forms and templates for your personal use within your organization. Please note that all such forms and policies should be reviewed by your legal counsel for compliance with applicable law, and should be modified to suit your organization’s culture, industry, and practices. Neither members nor non-members may reproduce such samples in any other way (e.g., to republish in a book or use for a commercial purpose) without SHRM’s permission. To request permission for specific items, click on the “reuse permissions” button on the page where you find the item.
Former pharmaceutical executive Alex Azar is promising he'll use his new role as secretary of the U.S. Department of Health and Human Services (HHS) to tackle the rising costs of prescription drugs.
voted Jan. 24 to confirm him to the role. He was
nominated for the position in November by President Donald Trump.
Azar ran Indianapolis-based Ely Lilly & Co.'s U.S. operations from June 2007 until last year and before that served as HHS general counsel and deputy secretary under President George W. Bush. Tom Price, the past HHS chief, resigned after reports that he used an excessive amount of government funds for private jet travel.
Jan. 9 hearing before the Senate Finance Committee,
Azar testified that his insider knowledge "of how insurance, manufacturers, pharmacy and government programs work together" would help him to address ways to moderate drug price increases "while still encouraging discovery [of new pharmaceuticals] so Americans have access to high-quality care."
While there is no "silver bullet" to fix the complex issue of drug pricing, Azar told the Senate committee, he would support policies to ensure robust market competition for both generic and brand-name drugs and to "create a viable and robust
biosimilar market also, to compete against branded companies in that high-cost
He said he intended to "go after any types of 'gaming' or exploitation" of branded drug patents by pharmaceutical firms so they can delay competition from generic versions of a drug and to take steps to "create incentives that actually pull down those list prices so that when patients [need to] pay out of pocket at the pharmacy, they're not hit with that kind of [high] cost."
A Presidential Pledge
During his State of the Union address on Jan. 30, President Donald Trump said:
One of my greatest priorities is to reduce the price of prescription drugs. In many other countries, these drugs cost far less than what we pay in the United States. That is why I have directed my administration to make fixing the injustice of high drug prices one of our top priorities. Prices will come down.
Employers can also
design their drug plans to help control costs,
HR Magazine reported last year.
[SHRM members-only toolkit:
Managing Health Care Costs]
"Through advertising and marketing, the pharma industry has built demand and preference for name-brand drugs by both the doctors who prescribe them and the patients that fill those prescriptions," said David Henka, president and CEO at RxTE Health, a pharmacy benefit management firm. "While these name-brand drugs are effective, there are oftentimes less expensive and equally-as-effective drugs available. The question is, how do we get patients to switch to these generic pharmaceuticals?"
SHRM Online that one solution is to "incentivize the selection of the lowest-cost drug option within a therapeutic category" by providing cost incentives that prompt consumers to switch to a lower-cost alternative that achieves equivalent clinical outcomes.
"We've seen time and again that more products lead to lower costs and [that] incentives to pay for [prescription drugs] based on their value help improve outcomes," said Joel White, president of the Council for Affordable Health Coverage (CAHC) in Washington, D.C., which last year
proposed a set of market-based reforms to lower the cost of prescription drugs and health care. "As policy makers look for solutions to lower costs, we believe it is important to offer reforms firmly rooted in competitive markets and incentives that promote value, innovation, transparency and appropriate access to treatment."
Congratulations to America’s new Secretary of @HHSGov, Alex Azar! pic.twitter.com/Y9inQaCt7o— Donald J. Trump (@realDonaldTrump) January 29, 2018
Congratulations to America’s new Secretary of @HHSGov, Alex Azar! pic.twitter.com/Y9inQaCt7o
Was this article useful? SHRM offers thousands of tools, templates and other exclusive member benefits, including compliance updates, sample policies, HR expert advice, education discounts, a growing online member community and much more.
Join/Renew Now and let SHRM help you work smarter.
You have successfully saved this page as a bookmark.
Please confirm that you want to proceed with deleting bookmark.
You have successfully removed bookmark.
Please log in as a SHRM member before saving bookmarks.
Please sign in as a SHRM member before saving bookmarks.
Please purchase a SHRM membership before saving bookmarks.
An error has occurred
Recommended for you
Apply by March 23
SHRM’s HR Vendor Directory contains over 3,200 companies